A COPD case study will be assessed and discussed. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 guidelines will be analyzed and applied to the case study presented below. Patient monitoring, education strategies, and clinical end point of the chosen drug therapy will be identified. Sample dosages form, route, and frequency of administration based on patients’ health status will be justified. Finally, the efficacy of complementary and alternative medicine (CAM) will be evaluated.
Case Study
Mrs. Jones is a 56 years old Caucasian female complaining of feeling tired recently, not sleeping through the night, difficulty breathing with minimal exertion and hearing an audible wheezing sound. She noticed she is producing more productive …show more content…
Jones FEV1/FVC of 65% falls under the category of Gold Initiative for Chronic Obstructive Lung Disease (Gold) grade 3 severe airway limitations. Although Mrs. Jones does not have any hospitalization and exacerbation history in the past, her risk for exacerbation is pretty high ("Global Initiative For Chronic Obstructive Lung Disease," 2017). The patient reported that she has been using a short-acting bronchodilator specifically Albuterol inhaler more frequently than every 4 hours. This only shows that her current treatment is ineffective therefore stepping up her medication to a long-acting bronchodilator can be effective in relieving her symptoms. Her symptoms include worse productive cough, short of breath with minimal exertion, feeling tired lately, and sleepless night that leads to a COPD Assessment Test (CAT) score of greater than 10. Unfortunately, MMRC breathlessness test cannot be calculated with the above case study health information. Therefore, Mrs. Jones pharmacological treatment for COPD falls under group B algorithm. Group B algorithm is the treatment of long-acting bronchodilators (monotherapy of either long-acting muscarinic drug (LAMA) or long-acting beta2 antagonist (LABA) or a combination of both) therapy for persistent symptoms. Bronchodilators medication can increase FEV1, change airway smooth muscle tone, and improve expiratory flow, which can lead to airway widening. LAMA can prolong binding to M3 receptors which can lengthen bronchodilator
Case Study
Mrs. Jones is a 56 years old Caucasian female complaining of feeling tired recently, not sleeping through the night, difficulty breathing with minimal exertion and hearing an audible wheezing sound. She noticed she is producing more productive …show more content…
Jones FEV1/FVC of 65% falls under the category of Gold Initiative for Chronic Obstructive Lung Disease (Gold) grade 3 severe airway limitations. Although Mrs. Jones does not have any hospitalization and exacerbation history in the past, her risk for exacerbation is pretty high ("Global Initiative For Chronic Obstructive Lung Disease," 2017). The patient reported that she has been using a short-acting bronchodilator specifically Albuterol inhaler more frequently than every 4 hours. This only shows that her current treatment is ineffective therefore stepping up her medication to a long-acting bronchodilator can be effective in relieving her symptoms. Her symptoms include worse productive cough, short of breath with minimal exertion, feeling tired lately, and sleepless night that leads to a COPD Assessment Test (CAT) score of greater than 10. Unfortunately, MMRC breathlessness test cannot be calculated with the above case study health information. Therefore, Mrs. Jones pharmacological treatment for COPD falls under group B algorithm. Group B algorithm is the treatment of long-acting bronchodilators (monotherapy of either long-acting muscarinic drug (LAMA) or long-acting beta2 antagonist (LABA) or a combination of both) therapy for persistent symptoms. Bronchodilators medication can increase FEV1, change airway smooth muscle tone, and improve expiratory flow, which can lead to airway widening. LAMA can prolong binding to M3 receptors which can lengthen bronchodilator